All In Biotech

Drug Trial Radar · NCT00762112

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

A Long-Term, Open-Label, Phase 3a Safety Study of Oral TAK-559 (32 mg QD) in the Treatment of Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Nov 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

316

Actual

Start

Nov 2003

Primary completion

Dec 2004

Study completion Dec 2004

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 30, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 25 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the long-term safety of TAK-559, once daily (QD), in subjects with Type 2 Diabetes.

Conditions

  • Diabetes Mellitus

Interventions

  • TAK-559Drug

    TAK-559 32 mg, tablets, orally, once daily for up to 24 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in clinical laboratory hematology tests.Time frame: Week 2 and Months 6, 12, 18, and Final Visit
  2. Change from baseline in clinical laboratory chemistry tests.Time frame: Week 2 and Months 6, 12, 18, and Final Visit
  3. Blood pressure measurements.Time frame: All visits.
  4. Pulse measurements.Time frame: All visits.
  5. Body weight.Time frame: All visits.
  6. Physical examinations.Time frame: Months 6, 12, 18, and Final Visit
  7. 12-lead electrocardiogram.Time frame: Months 6, 12, and Final Visit
  8. Adverse event occurrence.Time frame: All visits or at occurrence

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.